Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netakimab in active ankylosing spondylitis
NCT07277179Phase 3Completed
- Sponsor
- SPH-BIOCAD
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of netakimab in ankylosing spondylitis (AS), sponsored by SPH-BIOCAD. Started Mar 2023; status: completed.
02
Drugs
netakimab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07277179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277179.